Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Income (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Net Income for 11 consecutive years, with -$77.4 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 218.7% to -$77.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$136.8 million through Dec 2025, down 274.75% year-over-year, with the annual reading at -$130.3 million for FY2025, 68.27% down from the prior year.
  • Net Income for Q4 2025 was -$77.4 million at Cartesian Therapeutics, down from -$19.5 million in the prior quarter.
  • The five-year high for Net Income was $15.0 million in Q2 2024, with the low at -$196.7 million in Q4 2023.
  • Average Net Income over 5 years is -$20.4 million, with a median of -$13.6 million recorded in 2024.
  • The sharpest move saw Net Income surged 5505.67% in 2022, then plummeted 3437.15% in 2023.
  • Over 5 years, Net Income stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then tumbled by 3437.15% to -$196.7 million in 2023, then surged by 87.66% to -$24.3 million in 2024, then crashed by 218.7% to -$77.4 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$77.4 million, -$19.5 million, and -$20.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.